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INTRODUCTION
Allergen immunotherapy has been widely applied to patients
with asthma and rhinitis due to its favorable effects (1). Regar-
ding the mechanism of allergen immunotherapy, recent stud-
ies have emphasized the role of immunomodulating cytokines
such as IL-10, IL-12 and TGF 1 to effect on T and B cells
(2-4). Japanese hop (Hop J), a weed belonged to Cannabinaceae
family is widespread in both rural and urban areas of Korea.
It has been considered one of the major causative pollens of
autumn pollinosis in this country (5). We reported a prelim-
inary study showing a favorable clinical and immunologic
effect after the one-year immunotherapy with Hop J pollen
extracts (6). It is essential to extend the study period and
observe the mechanism of Hop J pollen immunotherapy. To
the best of our knowledge, this is the first study to observe
changes of serum cytokines with clinical parameters during
the three years’ immunotherapy with Hop J pollen extracts. 
MATERIALS AND METHODS
Preparation of Hop J immunotherapy extracts
Immunotherapy extract was prepared as described before
(5). An adequate amount of pollens was collected in the Suwon
area during the last 4 weeks of September 2003. The pollens
were defatted, dried, and sent to Allergopharma Co., Germany
for ‘‘Depo-Hop J’’ preparation, which was used for skin prick
test and immunotherapy. Standardization process was carried
out and presented as protein nitrogen units (PNU). The ini-
tial preparation was composed of three serial vials with stre-
ngths 1 (25 PNU), 2 (250 PNU), and 3 (2,500 PNU). For
the maintenance treatment, vial 3 (2,500 PNU) was used,
and was administered monthly for 3 yr. The initial dose was
0.1 mL, and the maximum tolerable dose was decided on an
individual basis. The extracts were lyophilized, which was
used for ELISA and IgE-immunoblot analysis.
Twenty patients (13 asthma with rhinitis and 7 hay fever)
were enrolled. Asthma severity was classified as mild to mod-
erate degrees based on the revised global initiative for asthma
guideline (2004) and they had suffered from seasonal aggra-
vation of asthmatic and rhinitis symptoms. All the patients
had high serum-specific IgE antibody to Hop J by ELISA,
as well as positive [>3+ (allergen to histamine ratio, A/H)]
responses to skin prick tests. To exclude allergen exposure
effect, Hop J immunotherapy was started in 1 month after
the pollen season. Patients’ sera were collected three times:
before, one year and three years after the immunotherapy. All
the patients gave their informed consent, and this study was
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Changes of Serum Cytokines After the Long Term Immunotherapy
with Japanese Hop Pollen Extracts
Japanese hop (Hop J) pollen has been considered as one of the major causative
pollen allergens in the autumn season. We developed a new Hop J immunothera-
py extract in collaboration with Allergopharma (Reinbeck, Germany) and investigat-
ed immunologic mechanisms during 3 yr immunotherapy. Twenty patients (13 asth-
ma with rhinitis and 7 hay fever) were enrolled from Ajou University Hospital. Sera
were collected before, 1 yr, and 3 yr after the immunotherapy. Changes of serum
specific IgE, IgG1, and IgG4 levels to Hop J pollen extracts and serum IL-10, IL-12,
TGF 1 and soluble CD23 levels were monitored by ELISA. Skin reactivity and air-
way hyper-responsiveness to methacholine were improved during the study period.
Specific IgG1 increased at 1 yr then decreased again at 3 yr, and specific IgG4 lev-
els increased progressively (p<0.05, respectively), whereas total and specific IgE
levels showed variable responses with no statistical significance. IL-10, TGF- 1 and
soluble CD23 level began to decrease during first year and then further decreased
during next two years with statistical significances. (p<0.05, respectively). In con-
clusion, these findings suggested the favorable effect of long term immunotherapy
with Hop J pollen extracts can be explained by lowered IgE affinity and generation
of specific IgG4, which may be mediated by IL-10 and TGF- 1.
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approved by the ethical commitee of Ajou University Medi-
cal Center, Suwon, Korea.
Changes of skin reactivity to Hop J and airway hyperre-
sponsiveness to methacholine
Skin prick tests were performed three times: before, one
year and three years after the immunotherapy and the skin
reactivity was presented as A/H ratio. Degrees of airway hy-
perresponsiveness to methacholine were measured out of sea-
son before and every year using the method previously des-
cribed (6).
Changes of serum total and specific IgE antibodies
Serum total IgE level was measured by Immuno-CAP sys-
tem (Pharmacia, Sweden) according to the manufacturer’s
instructions. A change of specific IgE level to Hop J was deter-
mined by ELISA according to the previously described method
(6). Briefly, microtiter plates (Costar, Corning, NY, U.S.A.)
were first coated with 100  L of Hop J pollen extract (1  g/
well) and left at 4℃ overnight. Each well was washed three
times with 0.05% Tween-phosphate-buffered saline (PBS-T),
and the remaining binding sites were blocked by incubation
with 200  L of 10% fetal bovine serum for 1 hr at room tem-
perature. Each well was washed three times and then incu-
bated for 1 hr at room temperature with 50  L of either the
patients’ sera (1:5 dilution) or control sera from 60 patients
who showed negative skin prick test responses to common
inhalant allergens and the Hop J pollen. After the wells were
washed three times with PBS-T, 100  L of 1:1,000 (vol/vol)
biotin-labeled goat anti-human IgE antibody (Sigma Co., St.
Louis, MO, U.S.A.) was added to the wells and incubated for
1 hr at room temperature. The wells were then washed three
times with PBS-T and incubated with 1:1,000 (vol/vol) strep-
tavidin peroxidase (Sigma Co.) for 30 min before another
washing step, which was followed by incubation with 100
L of 3.3′ , 5.5′ -tetramethylene benzidine in 0.05 M/L phos-
phate citrate buffer, pH 5.0, and 10 mL of 30% H2O2 in a
phosphate citrate buffer for 10 min at room temperature. The
reaction was stopped by the addition of 100  L of 2 N sulfu-
ric acid, and the absorbance was read at 450 nm by an auto-
mated reader.
ELISA for specific IgG1 and IgG4 antibodies to Hop J pollen
extracts 
Diluted patient serum or negative control serum (1:3 for
soluble IgG1 and 1:100 for soluble IgG4 in diluent buffer;
PBS containing 10% fetal bovine serum; 200  L) was added
to each well coated with Hop J pollen. After incubation for
1 hr at 25℃, the wells were washed three times with PBS-T.
After they were washed three times with PBS-T, 100  L of
1:1,000 (vol/vol) biotin-labeled goat anti-human IgG1 or IgG4
antibody (Sigma Co.) were added to the wells and incubat-
ed for 1 hr at room temperature. The wells were then washed
three times with PSB-T and incubated with 1:1,000 (vol/vol)
streptavidin peroxidase (Sigma Co.) for 30 min before another
washing step, which was followed by incubation with 100  L
of 3.3′ , 5.5′ -tetramethylene benzidine in 0.05 M phosphate
citrate buffer, pH 5.0, and 10 mL of 30% H2O2 in a phos-
phate citrate buffer for 10 min at room temperature. The reac-
tion was stopped by the addition of 100  L of 2 N sulfuric
acid, and the absorbance was read at 450 nm by an automated
reader. The antibody titer was expressed as arbitrary unit (A.U.)
absorbance values. The positive cut-off value was determined
as mean +3 standard deviations (SD) of 60 controls. All the
samples were run on the same day.
IgG4- immunoblot analysis using Hop J pollen extracts
12% SDS-PAGE and IgG4-immunoblot analysis were per-
formed under reducing conditions according to methods des-
cribed previously (6). The Hop J pollen extracts were mixed
with sample buffer (Tris-HCl 31 mM/L, 10% glycerol, 1%
SDS, 0.0025%, bromophenol blue, 2.5%  -mercaptoethanol,
pH 6.8) and heated in boiling water for 5 min. Then, stan-
dard marker (4 to 250 kDa; Novex, San Diego, CA, U.S.A.)
and the Hop J pollen extracts were loaded to 12% Tris-glycine
gel (Novex) for the separation of the antigens. Electrophore-
sis was performed with a Bio-Rad protein Mini cell for 90
min at 125 V. The gel was fixed and stained with Coomassie
brilliant blue. For immunoblotting, the proteins were trans-
ferred onto a polyvinylidene difluoride membrane (PVDF)
(Millipore Co., Bedford, MA, U.S.A.) in transfer buffer (Tris-
base 25 mM/L, glycine 193 mM/L and methanol 20%) with
a Bio-Rad transfer apparatus set at 200 mA for 90 min. The
blotted PVDF membrane was sliced into 4 mm widths. The
pieces of the membrane were blocked by using 5% skim milk
in Tris-buffered saline (TBS)-Tween (TBST) for 1 hr to block
nonspecific binding. Each membrane was then incubated
overnight at 4℃ with the patient or control sera that had
been diluted 1:10 v/v with 5% skim milk TBST. After wash-
ing, the membranes were incubated with anti-human IgG4
conjugated with biotin and streptavidine-alkaline phosphas-
tase (1:1,000 diluted, Sigma Co.) for one hour at room tem-
perature. After washing with TBST, the membrane was de-
veloped by using BCIP/NBT alkaline phosphatase substrate
(Sigma Co.).
ELISA for soluble CD23, IL-10, IL-12, and TGF- 1
To observe the changes of cell marker and cytokines, the
levels of IL-10, soluble CD23 (sCD23), IL-12 and TGF- 1
were measured by ELISA kits (Benger Med Systems, Vien-
na, Austria) according to the manufacturer’s guidance. The
changes between years were presented as the ratio between
two values.Serum Cytokines After Immunotherapy with Japanese Hop Pollen  807
Statistical analysis
Wilcoxon signed rank tests using SPSS (Chicago, IL, U.S.A.)
version 11.0 were applied to evaluate the statistical differences
between two values. A p value of 0.05 or less was regarded
as significant.
RESULTS
Changes of skin reactivity to Hop J and airway hyper-
responsiveness to methacholine 
Fig. 1A shows the changes of skin reactivity to Hop J. It
decreased after 1 yr of immunotherapy (p=0.019), however
further decrease was not noted from 1 to 3 yr (p=0.86). Air-
way hyperresponsiveness to methacholine tended to improve
at 1 yr (p=0.21) and improved further during next 2 yr (p=
0.05) as shown in Fig. 1B.
Changes of serum total specific IgE and soluble CD23
(sCD23) levels 
Fig. 2 shows the changes of serum specific IgE to Hop J
pollen extracts and sCD23 levels during 3 yr study period.
There were no significant changes in either total (data not
shown) or specific IgE antibody levels during the 3-yr of im-
munotherapy (p>0.05, respectively), however sCD23 level
began to decrease during the first year and significantly de-
creased during next two years. (p=0.003)
Initial 1 yr 3 yr
p=0.019
p=0.085
Fig. 1. Changes of skin reactivity (A) and PC20 methacholine (B) level during the 3 yr immunotherapy.
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Fig. 2. Changes of serum specific IgE (A) and sCD23 (B) level during the 3 yr immunotherapy.
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Changes of serum specific IgG1 and IgG4 antibodies to
Hop J
Fig. 3 shows the changes of serum specific IgG1 (Fig. 3A)
and IgG4 (Fig. 3B) antibodies to Hop J pollen extracts dur-
ing 3 yr immunotherapy. Specific IgG1 levels increased sig-
nificantly for first year with statistical significance (p<0.001),
and then decreased significantly during next two years (p=
0.0039). However, serum specific IgG4 levels began to increase
remarkably during the first year (p<0.0001) and increased
further until 3 yr with high statistical significance (p<0.001,
Fig. 3B).
Changes of IgG4 binding components within Hop J pollen
extracts
Fig. 4 shows the comparison of IgG4-binding components
within the Hop J pollen extracts using the sera of seven indi-
viduals showing remarkable increase of serum specific IgG4
level during the study period. Five components (94, 78, 22,
13, 7 kDa) showing remarkable increase of IgG4 binding in-
tensity were generated as shown in Fig. 4B.
Changes of serum IL-10 and TGF- 1 levels
Fig. 5 shows the changes of serum IL-10 (Fig. 5A) and TGF-
1 (Fig. 5B) levels during 3 yr immunotherapy. There were
no significant changes in serum IL-10 during the first year
(p=0.55), but decreased significantly during next two years
with statistical significance (p=0.05). TGF- 1 levels began
to decrease during the first year and decreased further during
next two years of immunotherapy with statistical significance
(p=0.01). There were no significant changes in serum IL-12
levels during 3 yr study period (data not shown).
Initial 1 yr 3 yr
p<0.001
p<0.001
Fig. 3. Changes of serum specific IgG1 (A) and specific IgG4 (B) level during the 3 yr’ immunotherapy.
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Fig. 4. Changes of IgG4 binidng components within the Hop J pollen extracts using the sera from 7 sensitized patients (1-7) and buffer con-
trol (B). a, before; b, 1 yr after immunotherapy; c, 3 yr after the immunotherapy.
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Large-scale studies evaluating the efficacy of subcutaneous
immunotherapy with inhalant allergens have been undertak-
en in patients with pollen asthma. Double-blind placebo con-
trolled studies using standardized vaccines have shown that
immunotherapy has a beneficial effect on bronchial symptoms
and/or decreases the need for asthma medications in both pollen
and house dust mite asthma (1, 7, 8).
Japanese hop pollen has been reported as one of the major
allergenic pollens in Far Eastern Asian countries (5) and there
has been no clinical trial looking at the effect of long term
allergen immunotherapy in the sensitized patients. This is the
first study to look at immunologic changes after long-term
Hop J pollen immunotherapy in the sensitized patients, in
which the study subjects were different from those enrolled
in our previous study (6). Pollens were collected from our
region and sent to Allergopharma Co, German. Alum pre-
cipitated immunotherapy extract was prepared according to
it’s standardized protocol. In this study, after 3 yr of immuno-
therapy, skin reactivity to allergen decreased earlier while fur-
ther decrease was not noted from 1 to 3 yr. The changes in
both skin reactivity and serum specific IgE levels to allergen
were not significantly decreased over 3 yr of immunotherapy.
However, airway hyperresponsiveness to methacholine im-
proved in some patients from first one year and significantly
improved during next two years. The change of sCD23 lev-
els was on the whole the same as that of airway hyperrespon-
siveness, it decreased significantly during next two years.
CD23, a differentiation marker of B cells and low affinity
IgE Fc receptor on antigen presenting cells, is continuously
cleaved by autolysis into soluble fragments called sCD23 that
have been found in patients with allergic diseases (10). Oth-
ers have reported a reduction of sCD23 levels during aller-
gen immunotherapy in allergic rhinitis and pollinosis (11,
12, 13). These findings suggest that both serum sCD23 levels
and airway hyperresponsiveness to methacholine can be im-
proved significantly after the Hop J pollen immunotherapy. 
These findings suggest that both skin reactivity and air-
way hyperresponsiveness to methacholine can be improved
significantly after the Hop J pollen immunotherapy. 
Regarding the mechanism of allergen immunotherapy, ear-
lier studies were focused on the changes of circulating anti-
bodies and effector cells, serum specific IgE antibody levels
were decreased, but specific IgG levels were increased (7, 8,
13). However, recent studies, which demonstrated an immu-
nomodulating effect from Th2 to Th1 responses, cytokine
regulation of the immune responses, and specific inhibition
or ablation of immune responses by means of tolerance induc-
tion (4, 5, 14, 15), have reinforced the importance and value
of allergen immunotherapy. In this study, the consistent find-
ings for increased levels of serum specific IgG1 and IgG4 anti-
bodies were confirmed, however specific IgG1 levels were
increased during first year and then decreased again, while
specific IgG4 increased progressively during the 3 yr study
period. These findings suggested that improvement in clini-
cal parameters after three years’ immunotherapy may be de-
rived from enhanced production of serum specific IgG4 and
lowered IgE affinity, not from the effect of specific IgG1 or
specific IgE. Generation of five IgG4 components were noted
from first year and their intensities were increased up to third
year.
There have been several reports demonstrating the involve-
ment of IL-10 and TGF- 1 to induce immunomodulating
effects after the allergen immunotherapy (2-4, 15). These two
cytokines could induce T-cell and B-cell suppression; IL-10
inhibits IgE and enhances IgG4 production in pollen allergy
studies (16, 17) and also it is a general inhibitor of prolifera-
Serum Cytokines After Immunotherapy with Japanese Hop Pollen  809
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Fig. 5. Changes of serum IL-10 (A) and TGF- 1 (B) level during the 3 yr immunotherapy.
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is a pleiotropic cytokine known to affect T cell proliferation,
differentiation, apoptosis, antigen presentation, effector func-
tions of macrophages, the expression of MHC class II15, 16
and I. Allergen immunotherapy could also affect IgE bind-
ing on B cell (10, 12, 18). These findings suggest that aller-
gen immunotherapy could induce TGF- and IL-10 produc-
tions from T cells, which result in reduction of specific IgE
with lowered affinity, but increased production of specific
IgG4 with high affinity, as suggested by a recent review (2).
In this study, serum IL-10 and TGF- 1 levels tended to de-
crease from first year and further decreased until third year.
The correlation data showed that the greater decrease in TGF-
1, the more decrease in sCD23, but higher increase of spe-
cific IgG4 antibody (data not shown). Although this is a lim-
ited study to explain these findings, the decreased level of
IL-10 and TGF- 1 may be explained by compartmentaliza-
tion of these two cytokines into major target tissues to pre-
sent immunomodulating effect there. In conclusion, we con-
firmed favorable effects in clinical parameters after the long-
term immunotherapy with Hop J pollen extracts, which could
be explained by increased production of specific IgG4 anti-
bodies and decreased IgE binding affinities in associations
with TGF- 1 and IL-10.
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